BrainCheck Aims to Revolutionize Alzheimer's Cognitive Screening

BrainCheck has launched an advanced cognitive care platform for early Alzheimer's diagnosis. The platform is accessible on any internet-enabled device and includes a three-minute assessment tool with a 92% sensitivity rate. New research from the University of Washington further validates BrainCheck's efficacy in tracking dementia progression, emphasizing its potential in enhancing cognitive care.

BrainCheck has unveiled its innovative solution for cognitive care, aiming to transform the early diagnosis of Alzheimer's disease. The unveiling took place at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, where researchers also presented new findings backing the platform's effectiveness.

The company's enhanced platform, described as the "next generation of cognitive care," offers a digital cognitive testing experience accessible from any device with internet connectivity – be it phones, tablets, or browsers. This ensures both patients and clinicians can access the platform, whether in-clinic or remotely.

Kim Rodriguez, CEO of BrainCheck, highlighted the significance of early diagnosis for Alzheimer's disease, the predominant form of dementia. She noted,

“Early diagnosis will help close this gap, and our platform empowers providers to easily access information on patients' cognitive health by offering a unique solution that includes screening, assessment, care planning, and monitoring. The latest version brings cognitive care to the next level, expanding access to our technology from any device or location, in-clinic or remote. We believe passionately that earlier is better and access should not be a barrier.”

One standout feature of BrainCheck's platform is the BrainCheck Screen, a three-minute assessment tool designed to swiftly gauge cognitive health. This user-friendly tool is composed of three tests that span various cognitive domains and can flag the need for more extensive testing. Trials involving a dataset of 99 individuals showed that the BrainCheck Screen can detect cognitive impairment with a 92% sensitivity rate and a 74% specificity rate.

Eric R. Penniman, D.O., Executive Medical Director at Summit Medical Group, expressed optimism about the new tool and pointed out:

“We've partnered closely with BrainCheck to share our clinical experience in cognitive testing and are pleased to see our feedback integrated into this latest release. With BrainCheck Screen, we'll be able to accurately and efficiently check cognitive health the same way we monitor blood pressure or cholesterol, allowing us to easily comply with Medicare requirements to assess cognitive function during annual wellness visits. It helps us rapidly determine which patients require additional testing and enhances our patient care.”

Researchers found the tool effective in tracking the progressive decline in patients' cognitive and functional abilities as they advanced through various stages of dementia.

Reza Hosseini Ghomi, MD, MSE, a neuropsychiatrist and Chief Medical Officer at BrainCheck, summarized the company's mission, stating, “Our research underscores BrainCheck's reliability in cognitive assessments and care planning. We're dedicated to offering solutions that genuinely improve the monitoring and assessment of brain health.”